尖端的药物输送技术使更多的药物能够特异性地与靶标结合,这对于将令人兴奋的新分子的益处转化为患者至关重要
CURRENT ROLE
2018
2017
2016
Featured publications
药物输送——增长势头.
Ashford, M. 药物输送——增长势头. Drug Deliv. and Transl. Res. 10, 1888–1894 (2020). http://doi.org/10.1007/s13346-020-00858-6
局部递送大分子以治疗结肠相关疾病.
巴克A,阿什福德M,布雷登DJ. Adv. Drug Deliv Rev (2018), 136-137: 2-27. Publication link.
新型多恶唑修饰树状大分子控制释放SN-38,肿瘤消退和胃肠道耐受性改善.
England RM, Hare JI, Barnes J, Wilson J, Smith A, Strittmatter N, Kemmitt PD, Waring MJ, Barry ST, Alexander C, Ashford MB. J Controlled Release (2017), 247, 73-85. Publication link.
一种新型的原位疏水离子配对(HIP)配方策略,用于纳米颗粒给药系统的临床产品选择.
J Controlled Release (2016), 229:106-19. 宋玉华,申娥,王宏,Nolan J, Low S, Parsons D, Zale S, Ashton S, Ashford M, Ali M. Publication link.
癌症纳米医学正在瞄准澳门第一赌城在线娱乐的目标?
拉默斯T, Kiessling F, Ashford M, Hennink W, Crommelin D, Storm G. Nat Rev Mater. (2016) 1(9): 16069. Publication link.
抗癌纳米药物发展的挑战与策略:产业视角.
Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Adv. Drug Deliv Rev (2016) 108, 25-38. Publication link.
聚恶唑啉接枝提高聚l -赖氨酸树状大分子的细胞相容性和官能团含量.
England R, Hare J, Kemmitt P, Treacher K, Waring M, Barry S, Alexander C, Ashford M. Polymer Chemistry (2016) 7:4609-17. Publication link.
极光激酶抑制剂纳米颗粒在体内靶向肿瘤具有良好的治疗指数.
Ashton S, Song YH, Nolan J, Cadogan E, Murray J, Odedra R, Foster J, Hall PA, Low S, Taylor P, Ellston R, Polanska UM, Wilson J, Howes C, Smith A, Goodwin RJ, Swales JG, Strittmatter N, Takats Z, Nilsson A, Andren P, Trueman D, Walker M, Reimer CL, Troiano G, Parsons D, De Witt D, Ashford M, Hrkach J, Zale S, Jewsbury PJ, Barry ST. 科学转化医学 (2016) 8:325ra17. Publication link.